AbbVie announced that the FDA has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. It is approved in combination with… read more.
The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new research… read more.
Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Imdylltra for the treatment of adult patients with extensive-stage… read more.
Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a… read more.
Almost 50 million Americans—disproportionately in rural areas—must drive 25 miles or more to access a gastroenterologist for diagnosis and treatment of issues involving the digestive system, according to… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) (UK) has 16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called… read more.
A meta-analysis evaluating bleeding risks among atrial fibrillation (AF) patients treated with therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) indicates that rates of major… read more.
Research from Saint Louis University (SLU) and the University of Nevada, Reno School of Medicine finds that some of the most-watched ads promote the worst food options for… read more.
Valneva SE reported further positive Phase III data in adolescents for its single-shot chikungunya virus (Chikv) vaccine, Ixchiq, which showed a sustained 98.3% sero-response rate one-year after single… read more.
New insights into what causes the painful and disruptive symptoms of urinary tract infections (UTIs) could offer hope for improved treatment. UTIs are one of the most prevalent… read more.
Roche announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults… read more.
Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
